A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients
about
Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infectionPolysaccharide immunomodulators as therapeutic agents: structural aspects and biologic functionThe influence of glucan polymer structure and solution conformation on binding to (1-->3)-beta-D-glucan receptors in a human monocyte-like cell line.Protective effects of betaglucin on myocardial tissue during myocardial infarction in rats and dogs.Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan.Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan.Effects of hyperbaric oxygen and Pgg-glucan on ischemic colon anastomosis.Effects of the medicinal mushroom Agaricus blazei Murill on immunity, infection and cancer.Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes.Structure elucidation and immunological function analysis of a novel β-glucan from the fruit bodies of Polyporus umbellatus (Pers.) Fries.Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.Improved antimicrobial host defense in mice following poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism.Beta glucan: health benefits in obesity and metabolic syndrome.Lectin site ligation of CR3 induces conformational changes and signaling.Effect of topically applied Saccharomyces boulardii on the healing of acute porcine wounds: a preliminary study.Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.Oral administration of a new soluble branched beta-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers.Natural and modified (1-->3)-beta-D-glucans in health promotion and disease alleviation.Biomedical issues of dietary fiber beta-glucan.Effect of BETA 1, 3/1, 6 GLUCAN on Upper Respiratory Tract Infection Symptoms and Mood State in Marathon Athletes.Isolation and structural characterization of a novel antioxidant mannoglucan from a marine bubble snail, Bullacta exarata (Philippi)β-Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers.An evidence-based systematic review of beta-glucan by the natural standard research collaboration.Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines.Fecal water from ileostomic patients consuming oat beta-glucan enhances immune responses in enterocytes.Protective effect of beta-glucan on lung injury after cecal ligation and puncture in rats.Manipulation of local and systemic host defence in the prevention of perioperative sepsis.Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future.Particulate β-glucan induces TNF-α production in wound macrophages via a redox-sensitive NF-κβ-dependent pathwayThe antioxidant effect of beta-Glucan on oxidative stress status in experimental spinal cord injury in rats.Scientific Opinion on the substantiation of a health claim related to Yestimun® and immune responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006Scientific Opinion on the safety of ‘yeastbeta-glucans’ as a Novel Food ingredientIdentification of the fungal ligand triggering cytotoxic PRR-mediated NK cell killing of Cryptococcus and Candida.The Complexity of Fungal β-Glucan in Health and Disease: Effects on the Mononuclear Phagocyte System.Effects of β-glucan on colon anastomotic healing in rats given preoperative irradiation.Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria.
P2860
Q24519010-9FCB5488-F049-4467-9668-E06D65727838Q24550711-937B3444-9CC0-4AA0-BD25-C5F30F5761D2Q30590844-2C989A9A-BB65-4E25-A4E1-313A83DA4D2CQ33552795-0A82FEFD-BE64-4BD5-8080-C8415232257CQ33574573-D46FB070-E44E-4845-9598-074C9E240174Q33999994-A60AA02B-C881-4A5A-9CE8-BD2B7767DDEBQ34012708-5063554A-ADF9-4AF6-B042-8D0AF0CB13E4Q34013716-F413A73F-6DD8-41C0-8537-C0F0AC21968EQ34159909-20FA6A20-6DD1-4B1F-8C2F-F1D01828B079Q34311062-B495127B-9BA5-4CF0-A263-17FF525EDB9AQ34577529-475A7E3D-C05A-488E-9B1C-33DAA9A94659Q35598181-6268072C-D298-4B1B-A5CF-CCCCA7BD27BDQ35609234-136DB320-06F7-4EC9-809B-8A55E75BE18DQ35728343-C5417842-195A-48E9-B3A2-4E5E3E32CFFDQ35986386-BD91AAE2-90C3-4166-A14E-EC5EF2CF4988Q36150511-203B7654-4B49-4E0A-9DA2-67D5717FD08EQ36347902-BC489EFB-D6F2-44BB-A470-AEBB47D1CD50Q36371491-D9D66322-7CC0-4788-ADA8-1E71AFE9E691Q36624381-04ADF85C-A635-4881-A9BF-6741EB9F8DB3Q37143339-30159E1E-B29B-4384-BEE5-83CFDA7A1D0EQ37369818-88A263F2-F0F0-421C-B253-115D85E53282Q37633371-0FABB8D9-9438-4FA9-A6F0-436606C87D28Q38264166-8C829684-7310-4328-B9EC-D2E8D85D3DE7Q38671575-0430A417-B060-42E0-8E01-5D6E78F3CF6DQ40182070-962CA4C3-DA85-4B87-9D42-9C4E05F8C702Q40432076-ADBBE0EF-164D-40DB-8503-B1BA53146AE8Q40931676-89FEAC9A-E964-42BF-B748-B58F2F74AD97Q41660956-7662D37D-D775-4A51-8635-288033CD82BDQ42240979-5733EE08-203D-401A-8055-F9E75F6FD2B8Q46466926-ADB19C21-958F-4A95-AE64-62976D433402Q47148380-B2F0F69C-493F-41EA-B928-29E1BFA8B502Q47149920-17CC1285-6183-4312-8185-5BD0D2CCC5C1Q50234398-B77428E8-B6E3-44A2-9A93-AD4C77755504Q54213239-C93E4337-E112-432A-9097-F8A2917875EEQ54417878-86829886-4604-459B-951B-8DF8ED9FC584Q54578649-6A208B9D-B1E3-4A4C-A086-685552314509
P2860
A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients
description
1994 nî lūn-bûn
@nan
1994 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A phase II multicenter, double ...... in high-risk surgical patients
@ast
A phase II multicenter, double ...... in high-risk surgical patients
@en
A phase II multicenter, double ...... in high-risk surgical patients
@nl
type
label
A phase II multicenter, double ...... in high-risk surgical patients
@ast
A phase II multicenter, double ...... in high-risk surgical patients
@en
A phase II multicenter, double ...... in high-risk surgical patients
@nl
prefLabel
A phase II multicenter, double ...... in high-risk surgical patients
@ast
A phase II multicenter, double ...... in high-risk surgical patients
@en
A phase II multicenter, double ...... in high-risk surgical patients
@nl
P2093
P3181
P1433
P1476
A phase II multicenter, double ...... in high-risk surgical patients
@en
P2093
A Hackford
B Bistrian
P G Fairchild
T J Babineau
P304
P3181
P356
10.1001/ARCHSURG.1994.01420350102014
P407
P577
1994-11-01T00:00:00Z